Compare Edgewise Therapeutics Inc. Common Stock (EWTX) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edgewise Therapeutics Inc. Common Stock vs New York Times Co — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.04 (market cap $3.94B), while New York Times Co trades at $66.9 (market cap $10.79B). The key difference: New York Times Co is far larger — about 2.7× Edgewise Therapeutics Inc. Common Stock's market cap, and New York Times Co pays a 1.38% dividend while Edgewise Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and New York Times Co for 82 Days on average.
| EWTX | NYT | |
|---|---|---|
Market Cap | $3.94B | $10.79B |
Volume | 810,104 | 2,034,872 |
Sector | Health | Media |
52-Week High | $48.35 | $85.86 |
52-Week Low | $14.89 | $54.86 |
Typical Hold Time | 0 Days | 82 Days |
Enterprise Value | $3.48B | $10.18B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
The New York Times Company (NYT) trades at $67.15, up 1.62% on the day, with a bearish technical signal but strong fundamental performance. Revenue grew to $2.82 billion in 2025, with net income reaching $344 million and a 12.17% margin. The company has beaten earnings estimates for the last three quarters, and analysts set a consensus price target of $81.50. Recent news includes a dividend declaration and ongoing litigation related to AI copyright issues.
Outlook is mixed: solid earnings growth and profitability support upside, but technical indicators and a shareholder lawsuit pose near-term risks. The stock offers value if it can maintain its growth trajectory, though investors should monitor legal developments and market sentiment closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Edgewise Therapeutics Inc. Common Stock
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
